Oramed Pharmaceuticals (ORMP) 10-Q2021 Q2 Quarterly report

Filed: 13 Apr 21, 4:19pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: anniversary, antigen, Biotech, Black, buy, chairman, committee, concurrently, confidential, Craig, Cutter, Cystron, dividend, Employment, establish, exhibit, harmful, intellectual, Kevin, member, Michael, Mill, Oravax, oversee, ownership, participation, particle, property, publicly, pvt, Rakin, refusal, Ridge, Schwabe, Secretary, serve, sqm, steering, sublicensee, sublicensing, Treasurer, triple, vaccine, Vasinikovich, vest, volatility

Removed: authoritative, continuing, corporate, earlier, earned, initiate, initiation, overview, pipeline, presentation, recorded, York

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

ORMP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the quarterly report of Oramed Pharmaceuticals Inc., or the Company, on Form 10-Q for the period ended February 28, 2021 as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Avraham Gabay, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, that to my knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: April 13, 2021	/s/ Avraham Gabay
	Avraham Gabay, Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.